AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing Of Claims:

- 1. (Previously submitted) An oral administration unit comprising a first active substance Tramadol or a pharmaceutically acceptable salt thereof, and a second active substance Diclofenac or a pharmaceutically acceptable salt thereof, wherein the two active substances are present in separate subunits so as to not impair the release profiles of the two active substances.
- 2. (Previously submitted) An oral administration unit according to claim 1, wherein the first active substance is a pharmaceutically acceptable salt of Tramadol selected from the group consisting of Tramadol hydrochloride, Tramadol hydrobromide, Tramadol sulfate, Tramadol phosphate, Tramadol fumarate, Tramadol succinate, Tramadol maleate, Tramadol nitrate, Tramadol acetate, Tramadol propionate, Tramadol malonate, Tramadol citrate, Tramadol tartrate, Tramadol benzoate, Tramadol salicylate, Tramadol phthalate and Tramadol nicotinate, and the second active substance is a pharamaceutically acceptable salt of Diclofenac selected from the group consisting of Diclofenac-sodium, Diclofenac-potassium, Diclofenac-calcium, Diclofenac-magnesium and Diclofenac-cholestyramine.

- 3. (Original) An oral administration unit according to claim 2, wherein the pharmacologically acceptable salt of Tramadol is Tramadol-HCl.
- 4. (Original) An oral administration unit according to claim 2, wherein the pharmacologically acceptable salt of Diclofenac is Diclofenac-Na.
- 5. (Original) An oral administration unit according to claim 1, wherein the active substances Tramadol and Diclofenac are contained in a quantitative ratio of 1:4 to 4:1.
- 6. (Original) An oral administration unit according to claim 5, wherein the quantitative ratio of Tramadol to Diclofenac is 1:2 to 3:1.
- 7. (Original) An oral administration unit according to claim 6, wherein the quantitative ratio of Tramadol to Diclofenac is 1:1 to 2.5:1.
- 8. (Original) An oral administration unit according to claim 1, wherein the subunits are each present in multiparticulate form.
- 9. (Original) An oral administration unit according to claim 1, wherein the subunits are each present in a form independently selected from the group consisting of microtablets, microcapsules, ion-exchange resinates, granules, active substance crystals, and pellets.

- 10. (Original) An oral administration unit according to claim 9, wherein the subunits are each present in the form of pellets or composite pellets produced by extrusion or spheronisation.
- 11. (Original) An oral administration unit according to claim 1, wherein at least one of the two active substances is present in a controlled release formulation.
- 12. (Original) An oral administration unit according to claim 11, wherein both active substances are present in a controlled release formulation.
- 13. (Original) An oral administration unit according to claim 11, wherein the controlled release formulation is effected via coating the at least one active substance, binding the at least one active substance to an ion-exchange resin, embedding the at least one active substance in a controlled release matrix, or a combination thereof.
- 14. (Original) An oral administration unit according to claim 13, wherein the at least one active substance is coated with a coating of a water-insoluble polymer or wax.

- 15. (Original) An oral administration unit according to claim 14, wherein the at least one active substance is coated with a water-insoluble polymer selected from the group consisting of polyacrylate resins and cellulose derivatives.
- 16. (Original) An oral administration unit according to claim 15, wherein the at least one active substance is coated with a water-insoluble alkylcellulose.
- 17. (Original) An oral administration unit according to claim 14, wherein the at least one active substance is coated with a water-insoluble ethylcellulose or poly(meth)acrylate polymer.
- 18. (Original) An oral administration unit according to claim 13, wherein the controlled release formulation is effected by embedding the at least one active substance in a controlled release matrix.
- 19. (Original) An oral administration unit according to claim 11, wherein the oral administration unit further comprises at least one of the active substances in a non-controlled release form.
- 20. (Original) An oral administration unit according to claim 1, wherein the oral administration unit is a sachet, a capsule or a tablet.

- 21. (Original) An oral administration unit according to claim 20, wherein the oral administration unit is a capsule or a pellet tablet.
- 22. (Original) An oral administration unit according to claim 20, wherein the oral administration unit is a rapidly decomposing tablet.
- 23. (Original) An oral administration unit according to claim 22, wherein the oral administration unit is a rapidly decomposing pellet tablet.
- 24. (Original) An oral administration unit according to claim 20, further comprising a release layer that effects a dissociation of the subunits from one another on contact with an aqueous body fluid.
- 25. (Original) An oral administration unit according to claim 20, wherein the oral administration unit is a tablet having a score mark to facilitate subdivision of the tablet.
- 26. (Original) An oral administration unit according to claim 20, wherein the oral administration unit has a gastric juice-resistant coating.
- 27. (Original) An oral administration unit according to claim 1, wherein the Tramadol and the Diclofenac are released in amounts of more than 70% and more than 60% by weight, respectively, within 16 hours.

- 28. (Original) An oral administration unit according to claim 1, wherein the Tramadol and the Diclofenac are released in amounts of more than 70% and more than 60% by weight, respectively, within 8 hours.
- 29. (New) An oral administration unit according to claim 27, wherein the oral administration unit is a capsule.